Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 27 May 2025
Reviewer's report:
Dear Authors,
This manuscript is a well-executed and valuable contribution to the field. The research is
methodologically sound, the argumentation is coherent, and the writing is clear and precise. I
did not identify any major concerns and have no further comments. Excellent work.
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 27 May 2025
Reviewer's report:
Dear Authors,
This manuscript is a well-executed and valuable contribution to the field. The research is
methodologically sound, the argumentation is coherent, and the writing is clear and precise. I
did not identify any major concerns and have no further comments. Excellent work.
Please review this paper.
user
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 27 May 2025
Reviewer's report:
Dear Authors,
This manuscript is a well-executed and valuable contribution to the field. The research is
methodologically sound, the argumentation is coherent, and the writing is clear and precise. I
did not identify any major concerns and have no further comments. Excellent work.
assistant